News Novo Nordisk cuts GLP-1 prices for cash buyers Novo Nordisk has said it will offer diabetes therapy Ozempic at $499 per month for cash-paying customers in the US.
News Under pressure from Trump, Lilly hikes Mounjaro prices in UK Lilly has said it will raise the UK list price of its diabetes and obesity therapy Mounjaro to bring it into parity with other European markets.
News Lilly-backed scheme aims to help UK improve obesity care Tens of thousands of NHS patients living with obesity could get help to reduce their weight through a partnership between the UK and Eli Lilly.
News Apple partners with FuturHealth on weight loss An alliance between Apple and FuturHealth will combine GLP-1 weight-loss treatment with the tech giant's Fitness+ subscription.
News Lilly weakens on oral weight-loss drug data Shares in Eli Lilly have come under pressure after reporting the results of a phase 3 trial of oral weight-loss candidate orforglipron.
News Bayer gets swift review for Kerendia in type 1 diabetes FDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
